Who
Robert W. Duggan
Director and 10% owner
Company insider
Files Form 4 as: Co-Chief Executive Officer, Summit Therapeutics; Director and 10% owner, Pulse Biosciences; 10% owner, Achaogen; Chairman and CEO, Pharmacyclics; Director, Intuitive Surgical.
In numbers
- Trades disclosed
- 916
- Buys
- 128
- Sells
- 60
- Bought
- $1.0B
- Sold
- $130.4M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 5 Jan 2006
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 2 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 12 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $50.0M3,810,000 at $13.12 | filing |
| 12 Jun 2026filed 12 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $50.0M3,810,000 at $13.12 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —12,495 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —12,495 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.5M100,000 at $14.60 | filing |
| 4 Jun 2026filed 4 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.5M100,000 at $14.60 | filing |
| 11 May 2026filed 15 May 2026 | PLSE Pulse BiosciencesMedical Devices | SEC FORM 4 Bought | $13.0M660,233 at $19.69 | filing |
| 11 May 2026filed 15 May 2026 | PLSE Pulse BiosciencesMedical Devices | SEC FORM 4 Bought | $13.0M660,233 at $19.69 | filing |
| 11 May 2026filed 11 May 2026 | PLSE Pulse BiosciencesMedical Devices | SEC FORM 4 Bought | $13.0M660,233 at $19.69 | filing |
| 11 May 2026filed 11 May 2026 | PLSE Pulse BiosciencesMedical Devices | SEC FORM 4 Bought | $13.0M660,233 at $19.69 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $98K11,232 at $8.76 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $98K11,232 at $8.76 | filing |
| 21 Oct 2025filed 23 Oct 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code A | $262.0M13,980,789 at $18.74 | filing |
| 21 Oct 2025filed 23 Oct 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code A | $5.0M266,808 at $18.74 | filing |
| 21 Oct 2025filed 23 Oct 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $500K26,680 at $18.74 | filing |
| 11 Sep 2025filed 11 Sep 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $90K5,000 at $18.07 | filing |
| 10 Sep 2025filed 12 Sep 2025 | PLSE Pulse BiosciencesMedical Devices | SEC FORM 4 Bought | $508K34,659 at $14.66 | filing |
| 10 Sep 2025filed 11 Sep 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $5.9M333,394 at $17.68 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Pulse Biosciences Partners With Clayman Thyroid Center To Expand Thyroid Nodule TreatmentPLSE · rttnews.com · 14 Oct 2026
0 headlines in the last 90 days name Robert W. Duggan; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.